RecruitingNCT05318755

China Gender-affirming Hormone Therapy Study

China Gender-affirming Hormone Therapy Study in Transgender Men and Women

Sponsor

Peking University Third Hospital

Enrollment

240 participants

Start Date

Apr 16, 2022

Study Type

OBSERVATIONAL

Conditions

Transgender Gender Incongruence

Summary

Data about transgender medical care, especially the gender-affirming hormone therapy (GAHT) is extremely insufficient in China. Few evidence exists in the physical and psychological effects of the hormonal treatment in Chinese transgender population. CGAHT is designed to describe the social and mental condition of transgender people who are seeking for formal GAHT, and to investigate the physical and psychological effects of GAHT on this population in China.

Eligibility

Min Age: 18 YearsMax Age: 40 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called GAHT for transgender men and a drug called GAHT for transgender women for people with gender incongruence and transgender. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 40 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.